Delivery Order SPE2DR25D3004-SPE2DR26FXLY3
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ropivacaine 0.2% in 400 mg/200 mL vials with a ceiling value of $1,431.54. This is a firm fixed price delivery order with an ultimate completion date of August 28, 2025, and represents a non-competitive set-aside contract. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $1,790.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL vials). The contract, which is a non-set-aside competitive award with an ultimate completion date of July 28, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This delivery order will be fulfilled from the vendor's facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,428.19 to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 ml in 200 ml units). This firm fixed-price delivery order is scheduled for completion by June 20, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation, reflecting the vendor's established capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL) in 200 mL units, with a contract ceiling value of $6,988.89. This is a firm fixed price delivery order with an ultimate completion date of October 27, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was awarded without a set-aside designation, indicating competitive...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,461.08 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Ropivacaine 0.2% 400 mg/200 mL in 200 mL units. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 2, 2025. The pharmaceutical product will be performed and delivered from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,410.92 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 ml, 200 ml units) with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a $5,112.84 delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Ropivacaine 0.2% 200 mg/100 mL in 100 mL quantities. This delivery order represents a firm fixed price contract with no set-aside designation, utilizing open competition. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of November 5, 2025. The delivery order is issued...
- The Defense Logistics Agency awarded a $4,400.42 delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL), a local anesthetic pharmaceutical product. The contract is a firm fixed-price delivery order with an ultimate completion date of August 27, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 8, 2025, for the supply of Ropivacaine 0.2% 200 mg/100 mL in 100 mL vials, with a ceiling value of $1,241.69. This competitively awarded, firm fixed-price delivery order is scheduled for completion by November 10, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ropivacaine 0.2% 400 mg/200 ml in 200 ml units, with a ceiling value of $2,147.31. This competitively awarded, firm fixed-price delivery order is set to be completed by September 19, 2025, with performance occurring at the vendor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's competitive standing...
- SPE2DR25D3004Indefinite Delivery Contract
- SPE2DR25D3004-SPE2DR26FXLY3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,868.26 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 ml in 200 ml units). This is a firm fixed price delivery order with an ultimate completion date of November 17, 2025, and represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor supporting federal medical procurement needs. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems globally. Ropivacaine, a local anesthetic, represents one of many critical medications within the company's extensive federal portfolio, which also includes specialty pharmaceuticals, vaccines, and medical devices distributed across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 11/14/25 |